Riskpilot← Back to searchSign inGet full accessNORDIC RANGE AS
ASActiveOrg 926816497Strømsveien 70, 2010 StrømmenWholesale of pharmaceutical and medical goods · NACE 4646Est. 20211 employees
Revenue 2024
NOK 2,7M
+703% vs 2023
EBITDA margin
0.9%
+101% vs 2023
Equity ratio
-6453.8%
Financial strength
Net profit 2024
NOK -525K
+84% vs 2023
| Revenue | NOK 2,7M | +703% |
| EBITDA | NOK 24K | +101% |
| Net profit | NOK -525K | +84% |
| Total assets | NOK 155K | -53% |
| Equity | NOK -10M | -6% |
| Employees | 1 | — |
Legal name
NORDIC RANGE AS
Org number
926816497
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
18. mars 2021
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Import, handel og agenturvirksomhet samt konsulent og informasjonsvirksomhet for farmasøytiske og lignende produkter og alt hva hermed står i forbindelse.
Address
Strømsveien 70, 2010 Strømmen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 332 | 2 668 |
| Staff expenses | −0 | −725 | −884 | −1 696 |
| EBITDA | −2 140 | −3 679 | −3 029 | 24 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −2 140 | −3 679 | −3 029 | 24 |
| Net financials | −24 | −277 | −337 | −548 |
| Profit before tax | −2 164 | −3 956 | −3 366 | −525 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −2 164 | −3 956 | −3 366 | −525 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 120 | 82 | 332 | 155 |
| Equity | −2 140 | −6 096 | −9 462 | −9 987 |
| Long-term debt | 0 | 0 | 9 333 | 9 620 |
| Short-term debt | 2 259 | 6 178 | 461 | 521 |
| Total debt | 2 259 | 6 178 | 9 794 | 10 142 |
EBITDA margin
0.9%
This company
15.8%
Market median
-94% vs market
20212024
Equity ratio
-6453.8%
This company
38.2%
Market median
-16995% vs market
20212024
Return on equity
-52456700.0%
This company
18.4%
Market median
-285090861% vs market
20212024
Net profit margin
-19.7%
This company
8.1%
Market median
-343% vs market
20212024
Asset turnover
17.24×
This company
1.12×
Market median
+1439% vs market
20212024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JF Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nordx Pharma Ab | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDIC RANGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Frederick Schnell | Chief Executive Officer | 0 companies |
| Kari Opheim | Board of Directors | 0 companies |
| Carl-David Bonnier | Chairman | 0 companies |
| Darlene Celeste Austria | Board of Directors | 0 companies |
| Kjell Rune Drevland | Chairman | 0 companies |